| Literature DB >> 33485847 |
Rutuja Umesh Savale1, Shovonlal Bhowmick2, Sameh Mohamed Osman3, Fatmah Ali Alasmary4, Tahani Mazyad Almutairi4, Dalal Saied Abdullah4, Pritee Chunarkar Patil1, Md Ataul Islam5.
Abstract
In the current study, a structure-based virtual screening paradigm was used to screen a small molecular database against the Non-structural protein 15 (Nsp15) endoribonuclease of <Entities:
Keywords: COVID-19; Molecular dynamics; Nsp15 endoribonuclease; SARS-CoV-2; Virtual screening
Year: 2021 PMID: 33485847 PMCID: PMC7825923 DOI: 10.1016/j.abb.2021.108771
Source DB: PubMed Journal: Arch Biochem Biophys ISSN: 0003-9861 Impact factor: 4.013
Fig. 1Schematic representation of screening steps of Nsp15 endoribonuclease modulators. More than eight thousand molecules considerd for VSW followed by binding free enrgy, pharmacokinetics assessment and MD simulation.
Fig. 2Two-dimensional representation of final Nsp15 endoribonuclease modulators. Each of the molecules represents with diverse kind of functional groups.
Fig. 3Binding interactions of proposed modulators with Nsp15 endoribonuclease. A number of important ligand-binding amino acid residues are labeled.
Fig. 4Binding mode of proposed modulators in Nsp15 endoribonuclease. All molecules were found fitted inside the receptor cavity of Nsp15.
Physiochemical and drug-likeness parameters of selected Nsp15 endoribonuclease modulators.
| Parameters | N1 | N2 | N3 | N4 | N5 |
|---|---|---|---|---|---|
| Formula | C20H24NO6 | C20H26N4O4 | C22H28NO6 | C12H13N2O4 | C15H18N5O3 |
| 374.41 | 386.44 | 402.46 | 249.24 | 316.34 | |
| 27 | 28 | 29 | 18 | 23 | |
| 6 | 10 | 6 | 6 | 9 | |
| 4 | 8 | 5 | 4 | 5 | |
| 99.23 | 107.72 | 108.84 | 65.91 | 86.44 | |
| 99.13 | 119.73 | 99.13 | 82.44 | 128.03 | |
| −2.81 | −2.24 | −3.25 | −1.15 | −1.74 | |
| Soluble | Soluble | Soluble | Very Soluble | Very Soluble | |
| High | High | High | High | High | |
| 0 | 0 | 0 | 0 | 0 | |
| 0.56 | 0.55 | 0.56 | 0.56 | 0.56 | |
| 4.29 | 3.19 | 4.42 | 2.08 | 3.12 | |
| LogP | 2.31 | 2.2 | 2.87 | 1.57 | 0.99 |
Molecular weight.
No of heavy atoms.
No of aromatic heavy atoms.
No of rotatable bonds.
Molar refractivity.
Topological polar surface area.
Solubility.
Solubility class.
Gastrointestinal absorption.
Violation of Lipinski's rule of five.
Bioavailability score.
Synthetic accessibility.
Predicted toxicity properties of selected Nsp15 endoribonuclease modulators – inhibitors.
| Toxicity properties | N1 | N2 | N3 | N4 | N5 |
|---|---|---|---|---|---|
| AMES toxicity | No | No | No | No | No |
| Max. tolerated dose (human) | −0.63 | −0.19 | −0.86 | 0.65 | 0.30 |
| hERG I/hERG II inhibitor | No/No | No/No | No/No | No/No | No/No |
| Oral Rat Acute Toxicity (LD50) | 2.33 | 1.47 | 2.21 | 1.50 | 2.07 |
| Oral Rat Chronic Toxicity (LOAEL) | 1.04 | 0.62 | 0.89 | 0.96 | 1.02 |
| Hepatotoxicity | No | No | No | No | No |
| Skin Sensitization | No | No | No | No | No |
| 0.41 | 0.27 | 0.44 | 0.09 | 0.27 | |
| Minnow toxicity | 2.53 | 2.00 | 2.62 | 3.06 | 3.10 |
Bioactivity and efficiency parameters of proposed Nsp15 endoribonuclease modulators.
| Molecule | |||||
|---|---|---|---|---|---|
| −11.539 | 0.425 | 0.368 | 1.154 | 5.435 | |
| −10.639 | 0.378 | 0.356 | 1.061 | 5.820 | |
| −10.507 | 0.362 | 0.346 | 1.046 | 7.928 | |
| −10.347 | 0.572 | 0.482 | 1.186 | 2.744 | |
| −10.361 | 0.443 | 0.415 | 1.067 | 2.234 |
Binding energy.
Ligand efficiency.
Ligand efficiency scale.
Fit quality.
Ligand-efficiency-dependent-lipophilicity.
Average, maximum and minimum RMSD, RMSF and RoG values of Nsp15 endoribonuclease bound with N1, N2, N3, N4 and N5.
| RMSD(nm) | |||||
|---|---|---|---|---|---|
| Complex | N1 | N2 | N3 | N4 | N5 |
| 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |
| 0.368 | 0.525 | 0.423 | 0.591 | 0.420 | |
| Average | 0.192 | 0.252 | 0.209 | 0.239 | 0.218 |
| RMSF (nm) | |||||
| 0.052 | 0.066 | 0.077 | 0.062 | 0.071 | |
| 0.463 | 0.431 | 0.559 | 0.631 | 0.593 | |
| Average | 0.122 | 0.147 | 0.171 | 0.136 | 0.158 |
| RoG (nm) | |||||
| 2.327 | 2.327 | 2.320 | 2.327 | 2.328 | |
| 2.465 | 2.507 | 2.514 | 2.470 | 2.506 | |
| Average | 2.384 | 2.402 | 2.404 | 2.381 | 2.396 |
Minimum.
Maximum.
Fig. 5RMSD of Nsp15 endoribonuclease backbone bound with N1, N2, N3, N4 and N5. All Nsp15 backbone except bound with N4 found to be equilibrated from the beginning of the simulation. Nasp15 backbone bound with N4 was seen equilibrated after about 30ns.
Fig. 6RMSF of individual amino acid residues of Nsp15 endoribonuclease. Amino acids of Nsp15 bound with all small molecules were fluctuated almost similar manner.
Fig. 7Radius of gyration for Nsp15 endoribonuclease. The range of the radius of gyration was found 2.30–2.50 nm. All trajectories showed the compactness of each complex throughout the simulation.
Fig. 8Binding free energies of Nsp15 endoribonuclease modulators. All molecules showed high negative binding free energy that signify the strong affinity of each molecules towards Nsp15.
Minimum, maximum and average values for binding free energy.
| Compounds | N1 | N2 | N3 | N4 | N5 |
|---|---|---|---|---|---|
| −633.190 | −1145.630 | −803.690 | −788.870 | −891.860 | |
| −124.450 | −39.471 | −15.998 | −28.991 | −43.135 | |
| −345.654 | −721.906 | −349.705 | −388.002 | −513.641 |